Trends
Every so often the Rising Trends database throws up a curve that does not make sense until you check what the drug regulator has actually done. This is one of those. The search term "glp-3 retatrutide" went from 720 monthly searches in May 2025 to 9,900 by June 2026 — a 519% climb year over year, with a peak of 12,100 in March 2026.
Here is the part that makes it unusual. Retatrutide is not approved. Not in the US, not anywhere. It is an investigational Eli Lilly molecule still working through Phase 3, and Lilly's own language is that it is "legally available only to participants in Lilly's clinical trials." Yet fourteen separate retatrutide search terms in our database are climbing at the same time, and the questions people are typing are not academic. They are asking about approval dates, results, manufacturers, forums, and China.
That is a demand curve forming around a drug before there is a drug to buy. Below is what retatrutide actually is, what the trial data genuinely shows, why the internet nickname "GLP-3" is wrong, and what the search terms at the bottom of the family are quietly telling us about a grey market that already exists.
Key takeaways:
- "glp-3 retatrutide" is up 519% year over year to 9,900 monthly searches, from 720 in May 2025 (Rising Trends data).
- Fourteen retatrutide search terms now total 21,420 monthly searches and are rising together — the signature of a category forming, not a single viral spike.
- Retatrutide is investigational and not approved by the FDA for any use. Lilly states it is legally available only to clinical trial participants.
- In the Phase 3 TRIUMPH-1 trial (2,339 randomized), participants on the 12 mg dose lost an average of 70.3 lbs, or 28.3% of body weight, over 80 weeks.
- The same trial reported nausea in 42.4% of the 12 mg group versus 14.8% on placebo, and discontinuation due to adverse events of 11.3% at 12 mg versus 4.9% on placebo.
- "retatrutide china" and "retatrutide forum" together run about 650 searches a month — a direct read on an unregulated research-chemical market for a drug that has never been through a regulatory review.
Let's get into it.
What we're seeing in the Rising Trends data
Here is the head term, "glp-3 retatrutide," over the last 14 months.
Search interest: "glp-3 retatrutide"
Monthly Google search volume (US) · Source: Rising Trends database
A single term breaking out is usually a news event. What makes this one worth writing about is that the whole family moved together. When we pulled every retatrutide query in the database, this is the shape of it.
The retatrutide query family: monthly search volume (June 2026)
Monthly Google search volume (US) · Source: Rising Trends database
Read the labels rather than the bars and the picture gets sharper. "retatrutide approval" is up 418% year over year. "retatrutide fda" is up 436%. "retatrutide drug" is up 878%. People are not searching for a product page. They are searching for a regulatory decision that has not happened. That is a very specific kind of demand, and it is the reason the rest of this article matters more than the growth rate does.
What a triple agonist actually is
The current generation of metabolic drugs works by copying gut hormones that your body releases after you eat. Semaglutide mimics one of them, GLP-1, which slows gastric emptying and signals fullness. Tirzepatide mimics two, adding GIP, which appears to improve how the body handles both glucose and fat storage.
Retatrutide, internally LY3437943, adds a third receptor: glucagon. That is the genuinely new part, and it is counterintuitive if you remember glucagon as the hormone that raises blood sugar. In this context the target is different. Glucagon receptor activity is understood to increase energy expenditure and to drive fat mobilisation in the liver — so instead of only reducing what goes in, the drug is also meant to increase what gets burned. Combining it with GLP-1 and GIP agonism is what lets the glucose-raising effect of glucagon be offset while the metabolic-rate effect is kept.
The liver signal is the cleanest evidence that the glucagon arm is doing something distinct. In a randomized Phase 2a trial published in Nature Medicine, 98 participants with metabolic dysfunction-associated steatotic liver disease saw mean relative liver-fat reductions at 24 weeks of 42.9%, 57.0%, 81.4% and 82.4% across the 1 mg, 4 mg, 8 mg and 12 mg doses, against a 0.3% increase on placebo. Normal liver fat, defined as under 5%, was reached by 86% of the 12 mg group and nobody on placebo. That is a small, early trial and it should be read as a hypothesis, not a conclusion. But it is the kind of result that explains why an entire pharmaceutical program was built around the molecule.
Why "GLP-3" stuck, and why it is wrong
The most-searched term in the whole family is a nickname the internet invented. There is no such thing as a GLP-3 receptor. GLP-1 and GLP-2 are real, distinct peptides; "GLP-3" is a made-up next-model-year label that reads as "the one after the one after semaglutide." The other community nickname, "Triple G," is closer to accurate because it at least gestures at three targets, though only two of the three (GLP-1 and glucagon) start with a G.
Why the wrong name won is not a mystery. "glp-3 retatrutide" pulls 9,900 monthly searches while "retatrutide glp," the technically-shaped version, pulls 880 — eleven times less. The nickname is easier to say, easier to remember, and it slots the drug into a version-number mental model that consumers already use for phones. Once a naming shortcut gets that much of a volume advantage, it is effectively permanent. Expect to be correcting it for years.
The related tell is "retatrutide name" at 590 searches a month, up 181% year over year. A meaningful number of people are searching specifically to find out what this thing is called, which is what happens when a molecule gets famous before it gets a brand.
Where it actually is in development
Retatrutide is in Phase 3. It has not been approved by the FDA or any other regulator, and Lilly's own trial communications describe it as an investigational molecule available only inside its clinical trials. That is the status as of this writing, and it is the single most important fact in this article.
What has read out so far is substantial. The pivotal obesity trial, TRIUMPH-1 (NCT05929066), randomized 2,339 adults with obesity, or overweight plus at least one weight-related condition, and without type 2 diabetes. According to Lilly's May 2026 results announcement, at 80 weeks participants lost an average of 47.2 lbs (19.0%) on 4 mg, 64.4 lbs (25.9%) on 9 mg and 70.3 lbs (28.3%) on 12 mg, against 5.5 lbs (2.2%) on placebo. The proportion reaching at least 30% total body weight loss was 45.3% on 12 mg versus 0.5% on placebo. In a study extension, participants with a baseline BMI of 35 or higher who stayed on 12 mg through 104 weeks averaged 85.0 lbs, or 30.3%.
These numbers are consistent with the earlier Phase 2 obesity trial published in the New England Journal of Medicine by Jastreboff and colleagues in 2023, which enrolled 338 adults and reported least-squares mean weight change at 48 weeks of −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg) and −24.2% (12 mg) versus −2.1% on placebo.
The diabetes side has read out too. In TRANSCEND-T2D-1, reported by Lilly in March 2026, 537 adults with type 2 diabetes on diet and exercise alone saw A1C fall by 1.7% to 2.0% across doses at 40 weeks, with 16.8% mean weight loss on 12 mg.
The program is much bigger than these three trials. Registered Phase 3 studies also cover type 2 diabetes with metformin, established cardiovascular disease, knee osteoarthritis, obstructive sleep apnea, chronic low back pain, weight-loss maintenance, a head-to-head against tirzepatide, and a 10,000-participant cardiovascular and kidney outcomes trial with an estimated completion date in February 2029. Outcomes trials of that size are what turn a weight-loss number into a claim that a drug prevents heart attacks — and they are not finished.
The part that does not make the headlines
Efficacy is only half of a Phase 3 readout, and the tolerability half is where retatrutide's dose story gets complicated.
In TRIUMPH-1, the common gastrointestinal adverse events at 4 mg, 9 mg and 12 mg against placebo were nausea at 28.6%, 38.4% and 42.4% versus 14.8%; diarrhea at 25.2%, 34.1% and 32.0% versus 13.5%; and vomiting at 10.6%, 22.8% and 25.3% versus 4.8%. GI effects are the well-known class effect for this whole drug family, and they scale with dose here as they do elsewhere.
The number that matters most is discontinuation. Participants stopped treatment because of adverse events at rates of 4.1% (4 mg), 6.9% (9 mg) and 11.3% (12 mg), compared with 4.9% on placebo. So the 4 mg dose was tolerated about as well as placebo while still producing 19% weight loss, and the headline 28.3% figure comes with more than double the placebo dropout rate. That trade-off is the actual clinical conversation, and it is exactly the nuance that gets flattened when a 28% number travels on its own.
In the type 2 diabetes trial the pattern held, with discontinuation due to adverse events of 5.1% on 12 mg versus 0.0% on placebo. The earlier Phase 2 obesity work also observed dose-dependent heart rate increases that peaked around 24 weeks before declining, and found that starting at a lower dose reduced GI events. None of this is disqualifying. It is the ordinary, unglamorous business of working out who a drug is actually for.
What "retatrutide china" and "retatrutide forum" are really measuring
Near the bottom of the family chart sit two terms that carry more weight than their volume suggests. "retatrutide china" runs 260 searches a month and "retatrutide forum" 390. Neither is a question about a prescription, because there is no prescription to get.
What they point at is a grey market in so-called research peptides: vials sold online, typically labelled for laboratory use or not for human consumption, marketed to consumers anyway. It is worth being blunt about what that means. These products have not been through any regulatory review of safety, quality or efficacy. They are not made under pharmaceutical manufacturing standards. Nothing verifies that the contents match the label, that the identity or purity is what is claimed, that the concentration is what is stated, or that the vial is sterile. Selling them for human use is illegal, and the "research use only" wording on the label is a legal fig leaf, not a safety feature.
Professional bodies have been consistent on the wider category. The Obesity Society's March 2026 statement on compounded GLP-1 products warns that large-scale production and marketing of these medicines "raises serious safety risks when products have not undergone the rigorous scientific and regulatory review required for FDA-approved therapies," and was prompted in part by reports of impurities found in compounded tirzepatide. A 2025 review in the Journal of the Endocrine Society documented the mechanics of how this goes wrong at scale: differing salt forms, non-standardised labelling and inconsistent concentrations across formulations, which the authors link directly to dosing errors. That review covers compounded copies of drugs that at least have approved reference products. Retatrutide does not even have that.
We are not going to describe how any of this is obtained, dosed or prepared, and there is no version of this where a home protocol is a reasonable idea. If you are thinking about metabolic treatment, the conversation to have is with a clinician about the medicines that have actually been approved. The point here is narrower and analytical: the search data shows an unregulated market forming ahead of a regulatory decision, and that gap is a genuine public-health problem rather than a curiosity.
Meanwhile, the incumbent moved to a price fight
The other half of this dataset says something equally interesting about where the current generation has landed. "tirzepatide" itself sits at 1,220,000 monthly searches, up 48% year over year. It is no longer an emerging term; it is infrastructure. And the terms growing fastest around it are not about efficacy at all.
| Term | Monthly searches | Year-over-year | | --- | --- | --- | | tirzepatide | 1,220,000 | +48% | | tirzepatide weight loss | 22,200 | −18% | | tirzepatide hair loss | 2,400 | +26% | | costco tirzepatide | 880 | +529% | | sesame tirzepatide | 390 | +457% | | cvs tirzepatide | 260 | +86% | | walmart tirzepatide | 170 | +1,600% |
Retailers and telehealth platforms in the query, not outcomes. "walmart tirzepatide" is up 1,600% year over year, "costco tirzepatide" peaked at 4,400 in January 2026, and the core "tirzepatide weight loss" term is actually down 18%. That is what a maturing category looks like: the argument shifts from does it work to what does it cost and where do I get it.
The oral wave lands in the same place. Lilly's orforglipron was approved by the FDA on April 1, 2026 as Foundayo for chronic weight management, on the strength of the ATTAIN program showing average weight loss of 27.3 lbs (12.4%) at the highest dose over 72 weeks. Our data caught the approval in real time: "orforglipron fda approval" spiked to 4,400 searches in April 2026, the exact month of the decision, from 1,600 in March. "orforglipron pill" now runs 6,600 a month, up 408% year over year, and "orforglipron cost" is up 336%.
So the market has split into two questions. The pill is competing on convenience and price, at self-pay pricing that starts far below injectable list prices. Retatrutide, if it ever gets approved, would compete at the opposite end on raw magnitude of effect. Those are different products for different people, and the search data is already sorting itself into both camps.
Where this is heading
The near-term milestone to watch is not a launch. It is a filing. Lilly has said further TRIUMPH results, including the type 2 diabetes and cardiovascular-disease trials, are coming, and a regulatory submission would follow that. Between a submission and a decision there is typically a year or more, and the large cardiovascular and kidney outcomes trial does not complete until 2029. Anyone reading the 2026 search curve as evidence that this drug is nearly available is misreading it.
Expect the search family to keep splitting. Right now the top of the family is definitional — what is it, who makes it, what is it called. As a filing approaches, the growth will rotate toward the regulatory and access terms that are already rising fastest: approval, FDA, cost, and eventually a brand name that does not exist yet. Watching which of those overtakes "glp-3 retatrutide" is the cleanest available signal of where the program actually is.
The grey market is the part that will get worse before it gets better. The gap between a spectacular published trial result and a legal prescription is the exact window unregulated sellers operate in, and this window is unusually long and unusually well-publicised. Enforcement against sellers of unapproved peptides has been running, but the search volumes suggest supply and demand have not gone anywhere.
The broader pattern is the one worth internalising. A drug with no approval, no brand, and no price generated 21,420 monthly searches across fourteen terms, on the strength of trial results alone. That is new. Clinical data now moves consumer demand directly, at internet speed, without a marketing campaign or a regulatory decision in between — and the systems built to protect people assume it moves the other way round.
Want to spot emerging shifts like this before they hit the headlines? Read our guide on how to identify market trends, explore the live retatrutide trend page, or browse what is breaking out right now on the Rising Trends dashboard.
